Limertinib Plus Radiotherapy

Phase 2Small molecule

TThe First Affiliated Hospital of Guangzhou Medical University

Limertinib Plus Radiotherapy is one of 20 small molecule programs targeting Brain Metastases. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain MetastasesNot yet recruiting

Brain MetastasesPhase 2

Not yet recruiting

Competition

Competitive Landscape

21 competitors in Brain Metastases

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 2

7 2

Keytruda

Merck & Co.

Phase 2

3 3

Namenda

AbbVie

Phase 2

2 4

Perjeta

Roche

Phase 2

1 5

Tukysa

Pfizer

Phase 2

1 6

Trodelvy

Gilead

Phase 2

1 7

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

3 8

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 9

Decadron

AAspen Global Incorporated

Phase 2

2 10

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Not yet recruiting

Brain Metastases

NCT07413952

Clinical

Trials by Indication[1]

Brain Metastases1 trial

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT07413952·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Limertinib Plus Radiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Limertinib Plus Radiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Limertinib Plus Radiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Guangzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Guangzhou Medical University

Limertinib Plus Radiotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Brain Metastases1 trial

References

Drug Info

Quick Facts

Related News